NCT04882917View on ClinicalTrials.gov

First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Advanced Solid Tumors
Interventions
DRUG

M4076

M4076 was administered orally.

Trial Locations (3)

77030

MD Anderson Center, Houston

78229

NEXT Oncology, San Antonio

M5G 1Z5

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

EMD Serono Research & Development Institute, Inc.

INDUSTRY